New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 18, 2012
12:11 EDTIBM, ILMN, APH, CREE, TXT, URI, STX, HAL, YHOO, INTC, RHHBYOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday, as disappointment with the reports of two blue chip technology companies weighed on the market. Stock futures were slightly lower during the pre-market trading session, leading to a lower open for the broader market. The averages have struggled since the opening bell, with little in the way of economic data to distract investors from the latest round of earnings reports... ECONOMIC EVENTS: Domestically, the Mortgage Bankers Association reported mortgage applications were up 6.9% from a week earlier, driven by refinancing. Crude oil inventories grew more than expected, while gasoline and distillates inventories shrank more than analysts forecast... COMPANY NEWS: IBM (IBM), Intel (INTC) and Yahoo (YHOO) all reported earnings after the close yesterday that beat consensus expectations, but only Yahoo shares rallied following the announcements. The declines in IBM, which saw its revenues miss expectations and its shares fall 2.5%, and Intel, down 2% after its gross margins were worse than last quarter, weighed heavily on the Dow. In contrast, Yahoo gained 3% as its revenue grew for the first time since Q3 of 2008, as noted by Piper Jaffray... Among other companies reporting earnings, advancers included Halliburton (HAL), Seagate (STX) and United Rentals (URI); decliners included Textron (TXT), Cree (CREE) and Amphenol (APH)... MAJOR MOVERS: Among the notable gainers were Catalyst Health Solutions (CHSI), up 31%, and SXC Health Solutions (SXCI), up 7.5%, as both stocks benefited from plans to merge the companies in a cash and stock transaction that implies a purchase price of $81.02 per Catalyst share. Also higher were shares of THQ Inc. (THQI), up 36%, after the company raised its expectations for Q4 on strong sales of its "Saints Row" game. Noteworthy losers included Genworth (GNW), down 21%, after announcing it would delay the IPO of its Australian mortgage insurance business until early 2013, and Chesapeake Energy (CHK), down 10%, after Reuters reported that its CEO took out as much as $1.1B in unreported loans over the last three years which could raise the possibility of conflicts of interest. Also lower were shares of Illumina (ILMN), down 2.5%, after Roche (RHHBY) decided not to extend its $51 cash tender offer for the company... INDICES: Near noon, the Dow was down 47.34, or 0.36%, to 13,068.20; the Nasdaq was down 10.72, or 0.35%, to 3,032.10; and the S&P 500 was down 3.79, or 0.27%, to 1,386.99.
News For IBM;INTC;YHOO;HAL;STX;URI;TXT;CREE;APH;ILMN;RHHBY From The Last 14 Days
Check below for free stories on IBM;INTC;YHOO;HAL;STX;URI;TXT;CREE;APH;ILMN;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 24, 2014
13:41 EDTRHHBYRoche to acquire InterMune for $74.00 per share
Roche (RHHBY) and InterMune (ITMN) announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3B on a fully diluted basis. This offer represents a premium of 38% to InterMune's closing price on August 22 and a premium of 63% to InterMune's unaffected closing price on August 12. The merger agreement has been approved by the boards of InterMune and Roche. Under the terms of the merger agreement, Roche will commence a tender offer no later than August 29 to acquire all outstanding shares of InterMune common stock, and InterMune will file a recommendation statement containing the unanimous recommendation of the InterMune board that InterMune's shareholders tender their shares to Roche. The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards. The acquisition of InterMune, a Brisbane, California based biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases, will allow Roche to broaden and strengthen its respiratory portfolio globally. Roche plans a smooth transition of InterMune employees and operations into the Roche organization, ensuring readiness for an expected launch of pirfenidone in the US in 2014. The closing of the transaction is expected to take place in 2014.
August 22, 2014
18:28 EDTYHOOAlibaba to begin selling used cars, Nikkei reports
Chinese e-commerce giant Alibaba plans to work with major dealership China Grand Automotive Services to sell used cars, Nikkei reports. Reference Link
07:08 EDTIBMIBM says China bank server business still alive, China Daily reports
Subscribe for More Information
05:28 EDTYHOOSoftbank capital raise could be used for acquisitions, Bloomberg says
Subscribe for More Information
August 21, 2014
11:44 EDTIBMHP hits 52-week high after solid revenue growth, positive analyst commentary
Subscribe for More Information
09:51 EDTCREEChina denies plans for raising LED tariffs, LEDinside reports
Subscribe for More Information
09:15 EDTHALEnerCom to hold a conference
The Oil & Gas Conference to be held in Denver on August 18-21 with webcasted company presentations to begin on August 21 at 10 am; not all company presentations may be webcasted. Webcast Link
09:03 EDTIBMIBM cloud technology selected by Wespac
Subscribe for More Information
09:02 EDTIBMIBM's private cloud resilence services selected by Ujjivan Financial
Subscribe for More Information
09:01 EDTIBMIBM partners with Veda
Subscribe for More Information
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
13:05 EDTINTCIntel and Unity collaborate to extend Android support across Intel-based devices
Subscribe for More Information
12:11 EDTYHOOStocks with call strike movement; UAL YHOO
United Continental (UAL) December 55 call option implied volatility decreased 3% to 42, Yahoo (YHOO) November 45 call option implied volatility increased 2% to 42 according to IVolatility.
11:49 EDTYHOOBofA/Merrill telecom services analysts hold an analyst/industry conference call
Analysts discuss the upcoming IPO of Alibaba, which is expected to launch early September 2014, on an Analyst/Industry conference call to be held on August 21 at 8 am.
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
August 19, 2014
11:32 EDTILMNLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
11:05 EDTIBMImperva seen as takeover candidate under new CEO
Subscribe for More Information
08:42 EDTIBMImperva new CEO has history of selling companies, says Sterne Agee
After Imperva (IMPV) appointed Anthony Bettencourt as its new CEO, Sterne Agee says that he has a history of selling companies. The firm believes that Imperva "would likely be an acquisition candidate" for a number of large tech companies such as Cisco (CSC), Juniper (JNPR), HP (HPQ), IBM (IBM), Check Point (CHKP), or F5 (FFIV). Sterne Agee believes that Imperva could be acquired for as much as $45 per share, and it keeps a Buy rating on the stock.
05:48 EDTYHOOStocks with implied volatility movement; AEO YHOO
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use